BCTXW (BriaCell Therapeutics) Cyclically Adjusted PB Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCTXW BriaCell Therapeutics Corp BCTXW
27 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics  (NAS:BCTXW) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BriaCell Therapeutics Cyclically Adjusted PB Ratio Related Terms


BriaCell Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Cyclically Adjusted PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 3.68 4.19 0.54 0.06

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.06 0.09 0.04 0.04

BCTXW vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.


BCTXW
27GF Score
BriaCell Therapeutics Corp BCTXW
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 is calculated as:

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book=Book Value per Share/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0/132.7364*132.7364
=0.000

Current CPI (Apr. 2026) = 132.7364.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201607 0.000 101.844 0.000
201610 0.000 102.002 0.000
201701 0.000 102.318 0.000
201704 0.000 103.029 0.000
201707 0.000 103.029 0.000
201710 0.000 103.424 0.000
201801 0.000 104.056 0.000
201804 0.000 105.320 0.000
201807 0.000 106.110 0.000
201810 0.000 105.952 0.000
201901 0.000 105.557 0.000
201904 0.000 107.453 0.000
201907 0.000 108.243 0.000
201910 0.000 107.927 0.000
202001 0.000 108.085 0.000
202004 0.000 107.216 0.000
202007 0.000 108.401 0.000
202010 0.000 108.638 0.000
202101 0.000 109.192 0.000
202104 0.000 110.851 0.000
202107 0.000 112.431 0.000
202110 0.000 113.695 0.000
202201 0.000 114.801 0.000
202204 0.000 118.357 0.000
202207 0.000 120.964 0.000
202210 0.000 121.517 0.000
202301 0.000 121.596 0.000
202304 0.000 123.571 0.000
202307 0.000 124.914 0.000
202310 0.000 125.310 0.000
202401 0.000 125.072 0.000
202404 0.000 126.890 0.000
202407 0.000 128.075 0.000
202410 0.000 127.838 0.000
202501 0.000 127.443 0.000
202504 0.000 129.102 0.000
202507 0.000 130.290 0.000
202510 0.000 130.603 0.000
202601 0.000 130.366 0.000
202604 0.000 132.736 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
27GF Score

Get the complete analysis for BCTXW

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price